A blood-based proteomic test reliably assesses individual patient prognosis to inform treatment decisions and reduce costs associated with overtreatment in lung cancer.
Read MoreCertain types of cancer—including some non-small cell lung cancers—abnormally overexpress PD-L1 on the surface of their cells.
Read More
FDA has granted premarket approval to Thermo Fisher Scientific for the first next-generation sequencing-based test that simultaneously screens tumor samples for biomarkers associated with three FDA-approved therapies for non-small cell lung cancer.
Read MoreA number of oncology centers have developed and implemented liquid biopsy tests not only for lung cancer, but for breast, colorectal, gynecologic, ovarian, prostate, and skin cancers as well.
Read More
The test provides highly sensitive results in 72 hours for non-small cell lung cancer patients.
Read More